GKOS - Glaukos Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
71.22
-0.41 (-0.57%)
As of 2:02PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close 71.63
Open 71.69
Bid 71.16 x 1000
Ask 71.28 x 900
Day's Range 70.16 - 71.78
52 Week Range 30.28 - 83.14
Volume 146,249
Avg. Volume 384,820
Market Cap 2.593B
Beta (3Y Monthly) 1.89
PE Ratio (TTM) N/A
EPS (TTM) -0.37
Earnings Date May 8, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 73.25
Trade prices are not sourced from all markets
  • Business Wire 7 days ago

    Glaukos Corporation to Release First Quarter 2019 Financial Results after Market Close on May 8

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release first quarter 2019 financial results after the market close on Wednesday, May 8, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 8, 2019.

  • Business Wire 9 days ago

    Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent® Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35.3% reduction in mean intraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.

  • Is Glaukos Corporation (NYSE:GKOS) A Volatile Stock?
    Simply Wall St. 12 days ago

    Is Glaukos Corporation (NYSE:GKOS) A Volatile Stock?

    If you own shares in Glaukos Corporation (NYSE:GKOS) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volat...

  • Markit 15 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Glaukos Corp NYSE:GKOSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for GKOS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding GKOS are favorable, with net inflows of $2.07 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition
    Zacks 22 days ago

    Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition

    Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.

  • GlobeNewswire 23 days ago

    New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire last month

    Pivotal Trial Results for Glaukos’ iStent inject® Published in Leading Ophthalmic Journal

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investigational Device Exemption (IDE) pivotal trial results for its next-generation iStent inject® Trabecular Micro-Bypass System have been published in Ophthalmology. Results of the iStent inject prospective, randomized, controlled, multicenter clinical trial, which included 505 mild-to-moderate primary open-angle glaucoma (POAG) subjects from 41 investigational sites, formed the basis for Food & Drug Administration approval of the device in June 2018.

  • Business Wire last month

    Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society Annual Meeting on March 14-17, 2019 at the Marriott ...

  • When Should You Buy Glaukos Corporation (NYSE:GKOS)?
    Simply Wall St. last month

    When Should You Buy Glaukos Corporation (NYSE:GKOS)?

    Glaukos Corporation (NYSE:GKOS), which is in the medical equipment business, and is based in United States, saw a significant share price rise of over 20% in the past couple ofRead More...

  • Business Wire last month

    International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent® Implantation in Combination with Cataract Surgery

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent® Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean intraocular pressure (IOP) to 14.7 mmHg after five years of follow-up.

  • Why Glaukos Stock Jumped 16.3% in February
    Motley Fool 2 months ago

    Why Glaukos Stock Jumped 16.3% in February

    Shares of this mid-cap ophthalmic medical tech and pharmaceutical company have soared 111% over the last year.

  • Thomson Reuters StreetEvents 2 months ago

    Edited Transcript of GKOS earnings conference call or presentation 27-Feb-19 9:30pm GMT

    Q4 2018 Glaukos Corp Earnings Call

  • Glaukos Corp (GKOS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool 2 months ago

    Glaukos Corp (GKOS) Q4 2018 Earnings Conference Call Transcript

    GKOS earnings call for the period ending December 31, 2018.

  • Business Wire 2 months ago

    Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2018.

  • Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline
    Zacks 2 months ago

    Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline

    Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire 3 months ago

    Glaukos Corporation to Release Fourth Quarter and Full Year 2018 Financial Results after Market Close on February 27

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release fourth quarter and full year 2018 financial results after the market close on Wednesday, February 27, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 27, 2019.

  • Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares This Year?
    Simply Wall St. 3 months ago

    Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Tamarack Capital Management’s Return, AUM, and Holdings
    Insider Monkey 3 months ago

    Tamarack Capital Management’s Return, AUM, and Holdings

    Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]

  • Hedge Funds Are Betting On Glaukos Corporation (GKOS)
    Insider Monkey 4 months ago

    Hedge Funds Are Betting On Glaukos Corporation (GKOS)

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]